Posted by Michael Wonder on 28 Jul 2020
Health Canada grants marketing authorisation with conditions for Gilead's Veklury (remdesivir) for the treatment of coronavirus disease 2019 (COVID-19)
28 July 2020 - Veklury is the first approved treatment option for COVID-19 in Canada.
Gilead Sciences Canada today announced that Health Canada has issued a marketing authorisation with conditions (Notice of Compliance with Conditions, or NOC/c) for Veklury (remdesivir).
Under this conditional authorisation, Veklury is indicated for the treatment of COVID-19 in adults and adolescents aged 12 years and older and weighing at least 40 kg, with pneumonia requiring supplemental oxygen.
